Previous close | 5.76 |
Open | 6.02 |
Bid | 5.85 x 100 |
Ask | 5.92 x 100 |
Day's range | 5.80 - 6.02 |
52-week range | 2.44 - 8.84 |
Volume | |
Avg. volume | 138,219 |
Market cap | 295.41M |
Beta (5Y monthly) | 1.45 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory BoardBOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Owen Wallace, Ph.D., the Company’s Chief Scientific Officer will be departing from his position to transition to a Chief Execut
MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose expected in Q2 2024 MRT-6160, a VAV1-directed MGD designed to treat systemic and neurological autoimmune diseases, progressing toward expected IND submission in Q2 2024 and initiation of Phase 1 SAD/MAD study midyear MRT-8102 nominated as first development candidate for NEK7 program, targeting disease
MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1β and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially applicable across a range of inflammatory disorders, metabolic disorders, as well as ocular and neurological diseases IND-enabling studies ongoing; IND submission anticipated in Q1 2025 BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology c